Clinical studies in 202 prostate cancer patients with one of the most promising candidates, [18F]rhPSMA-7 (Figure 10), showed exceptional imaging that was comparable to or even better than [68Ga]Ga-PSMA-11, especially in patients with low levels of PSA (prostate-specific antigen) [30,31]. This evidence concerns the gene KLK3 and prostate carcinoma.